Nascimento Ana Cláudia Mendes do, Dos Santos Diogo Fernandes, Antunes Douglas Eulálio, Gonçalves Maria Aparecida, Santana Marcela Araujo de Oliveira, Dornelas Bruno de Carvalho, Goulart Luiz Ricardo, Goulart Isabela Maria Bernardes
Postgraduate Program in Health Sciences, School of Medicine, Federal University of Uberlândia (UFU), Uberlândia, MG, Brazil.
National Reference Center for Sanitary Dermatology and Leprosy, Clinics' Hospital, School of Medicine, Federal University of Uberlândia (UFU), Uberlândia, MG, Brazil, Postgraduate Program in Health Sciences, School of Medicine, Federal University of Uberlândia (UFU), Uberlândia, MG, Brazil.
Int J Infect Dis. 2022 May;118:44-51. doi: 10.1016/j.ijid.2022.01.009. Epub 2022 Jan 10.
We aimed to characterize the profile of patients diagnosed with leprosy relapse and understand the influence of different multidrug therapy (MDT) treatments and initial disease presentation.
This retrospective study included patients diagnosed with leprosy relapse at a referral center in Brazil from 2013 to 2018. We analyzed their clinico-epidemiologic characteristics, laboratory data, and bacilloscopic tests. Survival analysis was used to determine the time elapsed until relapse according to the previous treatment and clinical forms of the disease.
A total of 126 cases of relapse were analyzed, which comprised 11.89% (126/1059) of the cases. The median time elapsed until a relapse was 10 years, and most patients had previously undergone 12 doses of MDT (40.48%; 51/126). Undergoing 24 doses of MDT was associated with a better prognosis regarding relapse over time compared with 6 or 12 doses of MDT therapy. Most cases of relapse were classified as multibacillary (96.03%; 121/126).
The incidence of relapse was greater than observed in other studies. The high percentage of multibacillary patients who had negative bacillary indices demonstrated that the bacillary index cannot be considered to be an essential criterion for relapse, especially concerning making an early diagnosis.
我们旨在描述麻风病复发患者的特征,并了解不同的多药联合治疗(MDT)方案及初始疾病表现的影响。
这项回顾性研究纳入了2013年至2018年在巴西一家转诊中心被诊断为麻风病复发的患者。我们分析了他们的临床流行病学特征、实验室数据和细菌学检查结果。生存分析用于根据先前的治疗方法和疾病的临床类型确定复发前经过的时间。
共分析了126例复发病例,占病例总数的11.89%(126/1059)。复发前经过的中位时间为10年,大多数患者之前接受了12剂MDT治疗(40.48%;51/126)。与6剂或12剂MDT治疗相比,接受24剂MDT治疗随着时间推移复发的预后更好。大多数复发病例被归类为多菌型(96.03%;121/126)。
复发率高于其他研究中的观察结果。细菌学指数为阴性的多菌型患者比例较高,这表明细菌学指数不能被视为复发的必要标准,尤其是在早期诊断方面。